SlideShare una empresa de Scribd logo
1 de 30
HYPERTENSION
• “Hypertension is defined as persistently
elevated arterial blood pressure (BP)”.
• Hypertension is the most common
cardiovascular disease.
• According to some studies, 60–80% of both
men and women will develop hypertension by
age 80.
• Sustained arterial hypertension damages
blood vessels in kidney, heart, and brain and
leads to renal failure, coronary disease, heart
failure, stroke, and dementia.
DIAGNOSIS
• The diagnosis of hypertension is based on
repeated, reproducible measurements of
elevated blood pressure.
• Diagnosis of hypertension depends on
measurement of blood pressure and not on
symptoms reported by the patient.
• Risk factors include smoking, metabolic
syndrome; e.g. obesity, Hyperlipidemia,
diabetes and a family history of cardiovascular
disease.
Classification of hypertension on the
basis of B.P.
Classification Systolic
(mm Hg)
Diastolic
(mm Hg)
Normal <120 <80
Pre-Hypertension 120–139 80–89
Stage 1 Hypertension 140–159 90–99
Stage 2 Hypertension ≥160 ≥100
Etiology of Hypertension
• A specific cause of hypertension can be
established in only 10–15% of patients, called
Secondary hypertension.
• Secondary hypertension is usually caused by
chronic kidney disease (CKD) or Reno-vascular
disease.
• Other conditions are Cushing syndrome,
Hyperparathyroidism, Pheochromocytoma,
Hyperthyroidism.
Etiology of Hypertension
• Some drugs that may increase BP include
Corticosteroids, Estrogens, Non-steroidal anti-
inflammatory drugs (NSAIDs), Amphetamines.
• Primary or Essential Hypertension has no
specific cause.
• Factors which contribute in development of
Primary Hypertension includes; Humoral
Disturbance, CNS Disturbance or high Na
intake.
ANTI HYPERTENSIVE DRUGS
Anti-Hypertensive drugs includes:
• A = ACE Inhibitors, ARBs, Alpha Blockers
• B = Beta Blockers
• C = Ca Channel Blockers
• D = Diuretics
• E = etc
ANTIHYPERTENSIVE DRUGS
1.DIURETICS
• which lower blood pressure by depleting the
body of sodium and reducing blood volume.
• Initially, diuretics reduce blood pressure by
reducing blood volume and cardiac output,
peripheral vascular resistance may increase.
• Diuretics are effective in lowering B.P. by 10–
15 mmHg in most patients.
DIURETICS
• Diuretics alone often provide adequate
treatment for mild or moderate essential
hypertension.
• Thiazide diuretics are appropriate for most
patients with mild or moderate hypertension
and normal renal and cardiac function.
• Most powerful diuretics are Loop Diuretics
e.g. Furosemide, are used in severe
Hypertension.
DIURETICS
• Potassium-sparing diuretics are useful both to
avoid excessive potassium depletion and to
enhance the natriuretic effects of other
diuretics.
 ADVERSE EFFECTS:
• In the treatment of hypertension, the most
common adverse effect of diuretics (except for
potassium-sparing diuretics) is potassium
depletion.
2. β-RECEPTOR BLOCKING AGENTS
• Propranolol; was the first β blocker to be
effective in hypertension and IHD.
• Propranolol (Non Selective) has now been
largely replaced by Cardioselective β blockers
such as metoprolol and atenolol.
• All β-adrenoceptor blocking agents are useful
for lowering blood pressure in mild to
moderate hypertension.
PROPRANOLOL
• Beta blockers have been shown to reduce
mortality after a myocardial infarction and
some also reduce mortality in patients with
heart failure.
• Propranolol decreases blood pressure
primarily as a result of a decrease in cardiac
output.
• Propranolol inhibits the stimulation of rennin
production by catecholamines (mediated by
β 1 receptors).
PROPRANOLOL
• The most important ADVERSE EFFECTS of the
β-blocking action occur in patients with
Bradicardia or cardiac conduction disease,
asthma and diabetes.
• When Propranolol is discontinued after
prolonged regular use some patients
experience a withdrawal syndrome,
manifested by nervousness, tachycardia &
increased blood pressure.
METOPROLOL & ATENOLOL
• Metoprolol and Atenolol, which are
Cardioselective, are the most widely used β
blockers in the treatment of hypertension.
• Cardioselectivity may be advantageous in
treating hypertensive patients who also suffer
from asthma, diabetes, or peripheral vascular
disease.
• Metoprolol is extensively metabolized by
CYP2D6 with high first pass metabolism.
• The drug has a relatively short half-life of 4–6
hours.
• Sustained-release Metoprolol is effective in
reducing mortality from heart failure
hypertension.
• ATENOLOL is not extensively metabolized and is
excreted primarily in the urine with a half-life of 6
hours.
• Recent studies have found Atenolol less effective
than Metoprolol in preventing the hypertension.
• Possible reason is once daily dose is not enough
to maintain the plasma conc. Of drug,
β-RECEPTOR BLOCKING AGENTS
• Betaxolol and Bisoprolol are β 1 -selective
blockers that are primarily metabolized in the
liver but have long half-lives.
• Because of relatively long half-lives, these
drugs can be administered once daily.
• Betaxolol at 10 mg/day and Bisoprolol at 5
mg/day.
• Increases in dosage to obtain a satisfactory
therapeutic effect.
Labetalol, Carvedilol & Nebivolol
• These drugs have both β-blocking and
vasodilating effects.
• Nebivolol is a β 1 -selective blocker with
vasodilating properties.
• D-Nebivolol has highly selective β 1 blocking
effects, while L-isomer causes vasodilation.
• The vasodilating effect may be due to an
increase in endothelial release of nitric oxide
via induction of endothelial nitric oxide
synthase.
3. CALCIUM CHANNEL BLOCKERS
• Calcium channel blockers (CCB) also reduce
peripheral resistance and blood pressure.
• The mechanism of action in hypertension is
“inhibition of calcium influx into arterial
smooth muscle cells”.
• Verapamil, Diltiazem and Dihydropyridines
family ( Amlodipine, Felodipine, Nicardipine,
Nifedipine.) are all equally effective in
lowering B.P.
3. CALCIUM CHANNEL BLOCKERS
• Verapamil has the greatest depressant effect
on the heart and may decrease heart rate and
cardiac output.
• Some studies shows an increased risk of
myocardial infarction or mortality in patients
receiving short acting Nifedipine for
hypertension.
• It is therefore recommended that short-acting
oral Dihydropyridines NOT be used for
hypertension.
• Nifedipine and the other Dihydropyridines
agents are more selective as vasodilators and
have less cardiac depressant effect.
• Sustained-release calcium blockers with long
half-lives provide smoother B.P. control and
are more appropriate for treatment of chronic
hypertension.
• IV Nicardipine and Clevidipine are available for
the treatment of hypertension when oral
therapy is not feasible.
• Parenteral Verapamil and Diltiazem can also
be used for the same indication.
4. ANGIOTENSIN-CONVERTING
ENZYME (ACE) INHIBITORS
• Captopril and other drugs in this class inhibit
the converting enzyme peptidyl dipeptidase
that hydrolyzes Angiotensin I to Angiotensin II
and inactivates bradykinin, a potent
vasodilator.
• Enalapril is an oral prodrug that is converted
by hydrolysis to Enalaprilat, with effects
similar to those of Captopril.
• Enalaprilat itself is available only for I.V. use,
primarily for hypertensive emergencies.
• Lisinopril is a lysine derivative of Enalaprilat.
• Benazepril, Fosinopril, Moexipril, Perindopril,
Quinapril, Ramipril, and Trandolapril are other
long acting members of the class.
• All are prodrugs, like Enalapril, and are converted
to the active agents primarily in the liver.
• ACE inhibitors have a particularly useful role in
treating patients with chronic kidney disease
because they diminish Proteinuria and stabilize
renal function.
• This effect is particularly valuable in diabetes, and
these drugs are now recommended in diabetes
even in the absence of hypertension.
TOXICITY
• Severe hypotension can occur after initial doses
of any ACE inhibitor.
• ACE inhibitors cause acute renal failure,
hyperkalemia, dry cough sometimes
accompanied by wheezing, and Angioedema.
• ACE inhibitors are contraindicated during the
second and third trimesters of pregnancy
because of the risk of fetal hypotension and renal
failure.
5.ANGIOTENSIN RECEPTOR BLOCKING
AGENTS
• Losartan and Valsartan were the first
marketed blockers of the angiotensin II type 1
(AT 1 ) receptor.
• Candesartan, Eprosartan, Irbisartan,
Telmisartan, and Olmesartan are also
available.
• They have no effect on bradykinin metabolism
and are therefore more selective blockers of
Angiotensin effects than ACE inhibitors.
• ARBs provide benefits similar to those of ACE
inhibitors in patients with heart failure and
chronic kidney disease.
• The adverse effects are similar to those
described for ACE inhibitors, including the
hazard of use during pregnancy.
• Cough and Angioedema can occur but are less
common with ARBs than with ACE inhibitors.
6.HYDRALAZINE
• Hydralazine, a hydrazine derivative, dilates
arterioles but not veins.
• The benefits of combination therapy are now
recognized, and Hydralazine may be used
more effectively, particularly in severe
hypertension.
• Hydralazine is well absorbed and rapidly
metabolized by the liver during the first pass,
so that bioavailability is low.
• The half-life of Hydralazine ranges from 1.5 to
3 hours, but vascular effects persist longer
than do blood concentrations, possibly due to
avid binding to vascular tissue.
• The most common adverse effects of
Hydralazine are headache, nausea, anorexia,
palpitations, sweating, and flushing.
7.SODIUM NITROPRUSSIDE
• Sodium nitroprusside is a powerful
parenterally administered vasodilator that is
used in treating hypertensive emergencies.
• Nitroprusside dilates both arterial and venous
vessels, resulting in reduced peripheral
vascular resistance and venous return.
• The action occurs as a result of activation of
Guanylyl Cyclase, either via release of nitric
oxide or by direct stimulation of the enzyme.
The result is increased intracellular cGMP,
which relaxes vascular smooth muscle.
• Nitroprusside is a complex of iron, cyanide
groups, and a nitroso moiety.
• It is rapidly metabolized by uptake into red
blood cells with liberation of cyanide. Cyanide
in turn is metabolized by the mitochondrial
enzyme in the presence of a sulfur donor, to
the less toxic thiocyanate. Thiocyanate is
distributed in extracellular fluid and slowly
eliminated by the kidney.
• Nitroprusside rapidly lowers blood pressure,
and its effects disappear within 1–10 minutes
after discontinuation.
• The drug is given by intravenous infusion.
• Sodium nitroprusside in aqueous solution is
sensitive to light and must therefore be made
up fresh before each administration and
covered with opaque foil.

Más contenido relacionado

Similar a Anti Hypertensive.pptx

Drugs used in hypertension
Drugs used in hypertensionDrugs used in hypertension
Drugs used in hypertensionGoutam Mallik
 
hypertension.pptx
hypertension.pptxhypertension.pptx
hypertension.pptxAhad Ali
 
lecture-3 hypertantion.pdf
lecture-3 hypertantion.pdflecture-3 hypertantion.pdf
lecture-3 hypertantion.pdfObsa2
 
Anti Hypertension.pptx
Anti Hypertension.pptxAnti Hypertension.pptx
Anti Hypertension.pptxSafiqul Islam
 
Antihypertensives | Classes of Drugs | Baro Receptor
Antihypertensives | Classes of Drugs | Baro ReceptorAntihypertensives | Classes of Drugs | Baro Receptor
Antihypertensives | Classes of Drugs | Baro ReceptorChetan Prakash
 
Antihypertensivedrugs
Antihypertensivedrugs Antihypertensivedrugs
Antihypertensivedrugs writngerrands
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...O. E.Nyandi PhD
 
Pharmacotherapy, Management of Hypertension, JNC 8 guidelines
Pharmacotherapy, Management of Hypertension, JNC 8 guidelinesPharmacotherapy, Management of Hypertension, JNC 8 guidelines
Pharmacotherapy, Management of Hypertension, JNC 8 guidelinesankitamishra1402
 
CVS-_Antihypertensives-_Beta_blockers.pdf
CVS-_Antihypertensives-_Beta_blockers.pdfCVS-_Antihypertensives-_Beta_blockers.pdf
CVS-_Antihypertensives-_Beta_blockers.pdfSanjayaManiDixit
 
Angina pectoris
Angina pectorisAngina pectoris
Angina pectorismzabihi
 
Antihypertensives Ch 1.pptx
Antihypertensives Ch 1.pptxAntihypertensives Ch 1.pptx
Antihypertensives Ch 1.pptxSolimanAbuDalfa
 
Anti adrenergic drugs
Anti adrenergic drugsAnti adrenergic drugs
Anti adrenergic drugsSabaShaikh76
 

Similar a Anti Hypertensive.pptx (20)

Drugs used in hypertension
Drugs used in hypertensionDrugs used in hypertension
Drugs used in hypertension
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensives
 
hypertension.pptx
hypertension.pptxhypertension.pptx
hypertension.pptx
 
lecture-3 hypertantion.pdf
lecture-3 hypertantion.pdflecture-3 hypertantion.pdf
lecture-3 hypertantion.pdf
 
No Title
No TitleNo Title
No Title
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Antihypertensive drugs 2015-16
Antihypertensive drugs 2015-16Antihypertensive drugs 2015-16
Antihypertensive drugs 2015-16
 
Ant ihypertensive
Ant ihypertensiveAnt ihypertensive
Ant ihypertensive
 
Anti Hypertension.pptx
Anti Hypertension.pptxAnti Hypertension.pptx
Anti Hypertension.pptx
 
Antihypertensives | Classes of Drugs | Baro Receptor
Antihypertensives | Classes of Drugs | Baro ReceptorAntihypertensives | Classes of Drugs | Baro Receptor
Antihypertensives | Classes of Drugs | Baro Receptor
 
Antihypertensivedrugs
Antihypertensivedrugs Antihypertensivedrugs
Antihypertensivedrugs
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
 
Pharmacotherapy, Management of Hypertension, JNC 8 guidelines
Pharmacotherapy, Management of Hypertension, JNC 8 guidelinesPharmacotherapy, Management of Hypertension, JNC 8 guidelines
Pharmacotherapy, Management of Hypertension, JNC 8 guidelines
 
Anti hypertensive
Anti hypertensiveAnti hypertensive
Anti hypertensive
 
CVS-_Antihypertensives-_Beta_blockers.pdf
CVS-_Antihypertensives-_Beta_blockers.pdfCVS-_Antihypertensives-_Beta_blockers.pdf
CVS-_Antihypertensives-_Beta_blockers.pdf
 
Angina pectoris
Angina pectorisAngina pectoris
Angina pectoris
 
Antihypertensives Ch 1.pptx
Antihypertensives Ch 1.pptxAntihypertensives Ch 1.pptx
Antihypertensives Ch 1.pptx
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Anti adrenergic drugs
Anti adrenergic drugsAnti adrenergic drugs
Anti adrenergic drugs
 
Htn1
Htn1Htn1
Htn1
 

Último

Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Pooja Bhuva
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxCeline George
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentationcamerronhm
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jisc
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxPooja Bhuva
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Jisc
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.pptRamjanShidvankar
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...Amil baba
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxJisc
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxEsquimalt MFRC
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxDr. Sarita Anand
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - Englishneillewis46
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxDr. Ravikiran H M Gowda
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxannathomasp01
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structuredhanjurrannsibayan2
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...ZurliaSoop
 

Último (20)

Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 

Anti Hypertensive.pptx

  • 1.
  • 2. HYPERTENSION • “Hypertension is defined as persistently elevated arterial blood pressure (BP)”. • Hypertension is the most common cardiovascular disease. • According to some studies, 60–80% of both men and women will develop hypertension by age 80. • Sustained arterial hypertension damages blood vessels in kidney, heart, and brain and leads to renal failure, coronary disease, heart failure, stroke, and dementia.
  • 3. DIAGNOSIS • The diagnosis of hypertension is based on repeated, reproducible measurements of elevated blood pressure. • Diagnosis of hypertension depends on measurement of blood pressure and not on symptoms reported by the patient. • Risk factors include smoking, metabolic syndrome; e.g. obesity, Hyperlipidemia, diabetes and a family history of cardiovascular disease.
  • 4. Classification of hypertension on the basis of B.P. Classification Systolic (mm Hg) Diastolic (mm Hg) Normal <120 <80 Pre-Hypertension 120–139 80–89 Stage 1 Hypertension 140–159 90–99 Stage 2 Hypertension ≥160 ≥100
  • 5. Etiology of Hypertension • A specific cause of hypertension can be established in only 10–15% of patients, called Secondary hypertension. • Secondary hypertension is usually caused by chronic kidney disease (CKD) or Reno-vascular disease. • Other conditions are Cushing syndrome, Hyperparathyroidism, Pheochromocytoma, Hyperthyroidism.
  • 6. Etiology of Hypertension • Some drugs that may increase BP include Corticosteroids, Estrogens, Non-steroidal anti- inflammatory drugs (NSAIDs), Amphetamines. • Primary or Essential Hypertension has no specific cause. • Factors which contribute in development of Primary Hypertension includes; Humoral Disturbance, CNS Disturbance or high Na intake.
  • 7. ANTI HYPERTENSIVE DRUGS Anti-Hypertensive drugs includes: • A = ACE Inhibitors, ARBs, Alpha Blockers • B = Beta Blockers • C = Ca Channel Blockers • D = Diuretics • E = etc
  • 8. ANTIHYPERTENSIVE DRUGS 1.DIURETICS • which lower blood pressure by depleting the body of sodium and reducing blood volume. • Initially, diuretics reduce blood pressure by reducing blood volume and cardiac output, peripheral vascular resistance may increase. • Diuretics are effective in lowering B.P. by 10– 15 mmHg in most patients.
  • 9. DIURETICS • Diuretics alone often provide adequate treatment for mild or moderate essential hypertension. • Thiazide diuretics are appropriate for most patients with mild or moderate hypertension and normal renal and cardiac function. • Most powerful diuretics are Loop Diuretics e.g. Furosemide, are used in severe Hypertension.
  • 10. DIURETICS • Potassium-sparing diuretics are useful both to avoid excessive potassium depletion and to enhance the natriuretic effects of other diuretics.  ADVERSE EFFECTS: • In the treatment of hypertension, the most common adverse effect of diuretics (except for potassium-sparing diuretics) is potassium depletion.
  • 11. 2. β-RECEPTOR BLOCKING AGENTS • Propranolol; was the first β blocker to be effective in hypertension and IHD. • Propranolol (Non Selective) has now been largely replaced by Cardioselective β blockers such as metoprolol and atenolol. • All β-adrenoceptor blocking agents are useful for lowering blood pressure in mild to moderate hypertension.
  • 12. PROPRANOLOL • Beta blockers have been shown to reduce mortality after a myocardial infarction and some also reduce mortality in patients with heart failure. • Propranolol decreases blood pressure primarily as a result of a decrease in cardiac output. • Propranolol inhibits the stimulation of rennin production by catecholamines (mediated by β 1 receptors).
  • 13. PROPRANOLOL • The most important ADVERSE EFFECTS of the β-blocking action occur in patients with Bradicardia or cardiac conduction disease, asthma and diabetes. • When Propranolol is discontinued after prolonged regular use some patients experience a withdrawal syndrome, manifested by nervousness, tachycardia & increased blood pressure.
  • 14. METOPROLOL & ATENOLOL • Metoprolol and Atenolol, which are Cardioselective, are the most widely used β blockers in the treatment of hypertension. • Cardioselectivity may be advantageous in treating hypertensive patients who also suffer from asthma, diabetes, or peripheral vascular disease. • Metoprolol is extensively metabolized by CYP2D6 with high first pass metabolism.
  • 15. • The drug has a relatively short half-life of 4–6 hours. • Sustained-release Metoprolol is effective in reducing mortality from heart failure hypertension. • ATENOLOL is not extensively metabolized and is excreted primarily in the urine with a half-life of 6 hours. • Recent studies have found Atenolol less effective than Metoprolol in preventing the hypertension. • Possible reason is once daily dose is not enough to maintain the plasma conc. Of drug,
  • 16. β-RECEPTOR BLOCKING AGENTS • Betaxolol and Bisoprolol are β 1 -selective blockers that are primarily metabolized in the liver but have long half-lives. • Because of relatively long half-lives, these drugs can be administered once daily. • Betaxolol at 10 mg/day and Bisoprolol at 5 mg/day. • Increases in dosage to obtain a satisfactory therapeutic effect.
  • 17. Labetalol, Carvedilol & Nebivolol • These drugs have both β-blocking and vasodilating effects. • Nebivolol is a β 1 -selective blocker with vasodilating properties. • D-Nebivolol has highly selective β 1 blocking effects, while L-isomer causes vasodilation. • The vasodilating effect may be due to an increase in endothelial release of nitric oxide via induction of endothelial nitric oxide synthase.
  • 18. 3. CALCIUM CHANNEL BLOCKERS • Calcium channel blockers (CCB) also reduce peripheral resistance and blood pressure. • The mechanism of action in hypertension is “inhibition of calcium influx into arterial smooth muscle cells”. • Verapamil, Diltiazem and Dihydropyridines family ( Amlodipine, Felodipine, Nicardipine, Nifedipine.) are all equally effective in lowering B.P.
  • 19. 3. CALCIUM CHANNEL BLOCKERS • Verapamil has the greatest depressant effect on the heart and may decrease heart rate and cardiac output. • Some studies shows an increased risk of myocardial infarction or mortality in patients receiving short acting Nifedipine for hypertension. • It is therefore recommended that short-acting oral Dihydropyridines NOT be used for hypertension.
  • 20. • Nifedipine and the other Dihydropyridines agents are more selective as vasodilators and have less cardiac depressant effect. • Sustained-release calcium blockers with long half-lives provide smoother B.P. control and are more appropriate for treatment of chronic hypertension. • IV Nicardipine and Clevidipine are available for the treatment of hypertension when oral therapy is not feasible. • Parenteral Verapamil and Diltiazem can also be used for the same indication.
  • 21. 4. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS • Captopril and other drugs in this class inhibit the converting enzyme peptidyl dipeptidase that hydrolyzes Angiotensin I to Angiotensin II and inactivates bradykinin, a potent vasodilator. • Enalapril is an oral prodrug that is converted by hydrolysis to Enalaprilat, with effects similar to those of Captopril. • Enalaprilat itself is available only for I.V. use, primarily for hypertensive emergencies.
  • 22. • Lisinopril is a lysine derivative of Enalaprilat. • Benazepril, Fosinopril, Moexipril, Perindopril, Quinapril, Ramipril, and Trandolapril are other long acting members of the class. • All are prodrugs, like Enalapril, and are converted to the active agents primarily in the liver. • ACE inhibitors have a particularly useful role in treating patients with chronic kidney disease because they diminish Proteinuria and stabilize renal function.
  • 23. • This effect is particularly valuable in diabetes, and these drugs are now recommended in diabetes even in the absence of hypertension. TOXICITY • Severe hypotension can occur after initial doses of any ACE inhibitor. • ACE inhibitors cause acute renal failure, hyperkalemia, dry cough sometimes accompanied by wheezing, and Angioedema. • ACE inhibitors are contraindicated during the second and third trimesters of pregnancy because of the risk of fetal hypotension and renal failure.
  • 24. 5.ANGIOTENSIN RECEPTOR BLOCKING AGENTS • Losartan and Valsartan were the first marketed blockers of the angiotensin II type 1 (AT 1 ) receptor. • Candesartan, Eprosartan, Irbisartan, Telmisartan, and Olmesartan are also available. • They have no effect on bradykinin metabolism and are therefore more selective blockers of Angiotensin effects than ACE inhibitors.
  • 25. • ARBs provide benefits similar to those of ACE inhibitors in patients with heart failure and chronic kidney disease. • The adverse effects are similar to those described for ACE inhibitors, including the hazard of use during pregnancy. • Cough and Angioedema can occur but are less common with ARBs than with ACE inhibitors.
  • 26. 6.HYDRALAZINE • Hydralazine, a hydrazine derivative, dilates arterioles but not veins. • The benefits of combination therapy are now recognized, and Hydralazine may be used more effectively, particularly in severe hypertension. • Hydralazine is well absorbed and rapidly metabolized by the liver during the first pass, so that bioavailability is low.
  • 27. • The half-life of Hydralazine ranges from 1.5 to 3 hours, but vascular effects persist longer than do blood concentrations, possibly due to avid binding to vascular tissue. • The most common adverse effects of Hydralazine are headache, nausea, anorexia, palpitations, sweating, and flushing.
  • 28. 7.SODIUM NITROPRUSSIDE • Sodium nitroprusside is a powerful parenterally administered vasodilator that is used in treating hypertensive emergencies. • Nitroprusside dilates both arterial and venous vessels, resulting in reduced peripheral vascular resistance and venous return. • The action occurs as a result of activation of Guanylyl Cyclase, either via release of nitric oxide or by direct stimulation of the enzyme. The result is increased intracellular cGMP, which relaxes vascular smooth muscle.
  • 29. • Nitroprusside is a complex of iron, cyanide groups, and a nitroso moiety. • It is rapidly metabolized by uptake into red blood cells with liberation of cyanide. Cyanide in turn is metabolized by the mitochondrial enzyme in the presence of a sulfur donor, to the less toxic thiocyanate. Thiocyanate is distributed in extracellular fluid and slowly eliminated by the kidney.
  • 30. • Nitroprusside rapidly lowers blood pressure, and its effects disappear within 1–10 minutes after discontinuation. • The drug is given by intravenous infusion. • Sodium nitroprusside in aqueous solution is sensitive to light and must therefore be made up fresh before each administration and covered with opaque foil.